

the amount of duties provided for by the Tax Code of the Russian Federation for drug registration by an average of 24%. In addition, the deadline for implementation the registration of MP has increased from 160 (Federal Law N61) to 210 (the EAEU Decision) calendar days.

Conclusions. The analysis showed that the requirements for the RD for MP with the entry into force of the EAEU Decision have changed significantly. There is many critical points related to the formation of RDs in the LP in accordance with the EAEC Decision. These include an increase in the complexity of the formation of RD for MP, an increase in financial costs during registration, and an increase in the duration of registration. The obtained data should be taken into account by pharmaceutical corporations for registration in accordance with the Rules of Registration and Examination of medicines in the EAEU.

GENERAL ISSUES ABOUT ANCHORING DRUGS

Nesterenko T. O.

Scientific supervisor: prof. Nemchenko A. S., assoc. prof. Podgaina M. V.

National University of Pharmacy, Kharkiv, Ukraine


tanyan393@gmail.com

Introduction. In our time, there is a very few information about the effect of anchoring drugs and their role on the human body in our country. But foreign sources indicate that their role is important and needs further research.

Aim. To analyze actual issues about anchoring drugs in Ukraine and abroad.

Materials and methods. Consideration of anchoring drugs as a target for binding to membranes have been analysed. The study of Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis has been describe.

Results and discussion. Anchoring drugs are any structure of drugs that provides stability for use in treatment, these structures are built into molecules. Bioavailability is a quantitative indicator of the ability drug to reach the systemic circulation. However, if the drug target is founded in the subcellular organelle, means that the drug can not achieve this and influence of the drug is minimized so will not be obtained. Membrane proteins, lipids, nutrients and some pathogens are assimilated in the cell to be aimed to individual subcellular compartments through exchange through the membrane. Recent approaches have revealed new ways of targeting a subcellular preparation, including the use of conjugation with cell surface receptor ligands or lipid anchors.



One of few studies has shown that Methotrexate courses are proceeded far longer than those of any other disease modifying anti-rheumatic drugs (DMARD), an superlative indicator of greater effectiveness and safeness. These data confirms that the methotrexate is an anchor and probably should be the first DMARD used in most patients with RA at this time.

Conclusions. So, if we will focus on the importance of subcellular targeting of drugs, in the specific lipid anchoring mechanism as a new strategy and its potential practice for the treatment of several diseases. As a result, in our country it is necessary to start research on the introduction of anchoring drugs in the therapy of diseases.